A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders

Sponsor
Hansoh BioMedical R&D Company
Study ID
NCT06212245
Phase
PHASE4
Status
Unknown

Conditions

  • Neuromyelitis Optica Spectrum Disorders

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Inebilizumab — DRUG
    Participants will receive IV inebilizumab 300 mg

Study Details

To assess the efficacy and safety of Inebilizumab in Chinese adult patients with neuromyelitis optica spectrum disorders.

Key Dates

Start date
Feb 25, 2024
Status verified
Jan 2024
Primary completion
Dec 25, 2024
Completion
Jun 25, 2025

Study Design

Enrollment
33 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Inebilizumab
    Participants will receive IV inebilizumab 300 mg

Primary Outcome Measure

Percentage of participants with NMOSD attack determined by the investigator [ Time Frame: Day 1 (Baseline) through Day 197 ]

Related Studies